Skip to content
AgridianDairy KB

Drug residue avoidance

Definition

Section titled “Definition”

Drug residue avoidance is the set of farm practices that keep animal drugs (mainly antibiotics, but also anti-inflammatories and other drugs) out of milk and meat above the legal tolerance that FDA sets in 21 CFR Part 556. A violative residue is a residue above tolerance, or any detectable residue of a drug that has no tolerance or is prohibited in food animals.

Who sets the rules:

  • FDA approves drugs, sets tolerances and withdrawal periods, and regulates extra-label use (AMDUCA; 21 CFR Part 530).
  • The PMO (Appendix N) requires residue screening of bulk milk tankers and sets what happens to a farm whose milk tests positive. See Grade A milk and the PMO.
  • USDA FSIS tests carcasses at slaughter; cull dairy cows are a common source of meat residue violations.
  • Industry programs (the National Dairy FARM Program, processor and cooperative programs) require a VCPR, written treatment protocols and treatment records.

Core practices, as laid out in the NMPF residue prevention manual:

  1. A valid VCPR and written treatment protocols from the herd veterinarian.
  2. Only approved drugs, used per label or under a written vet order for ELDU.
  3. Correct drug storage and labeling, with lactating-cow and non-lactating drugs kept separate.
  4. Every treatment recorded, with milk and meat withdrawal end dates.
  5. Treated animals clearly identified, and their milk kept out of the tank.
  6. Testing milk from treated cows before return to the tank when there is doubt (ELDU, a cow that calved early after dry-cow therapy, a bought-in cow).
  7. Training for everyone who treats or milks cows, with records.

Prohibited extra-label uses in food animals are listed in 21 CFR 530.41(a) (as of November 2026):

  • chloramphenicol; clenbuterol; diethylstilbestrol (DES);
  • dimetridazole, ipronidazole and other nitroimidazoles;
  • furazolidone; nitrofurazone;
  • fluoroquinolones; glycopeptides;
  • sulfonamide drugs in lactating dairy cattle, except approved use of sulfadimethoxine, sulfabromomethazine and sulfaethoxypyridazine;
  • phenylbutazone in female dairy cattle 20 months of age or older;
  • cephalosporins (not including cephapirin) in cattle, swine, chickens or turkeys when used for disease prevention, at unapproved doses, frequencies, durations or routes, or when the drug is not approved for that species and production class.

How to pull it in DC305

Section titled “How to pull it in DC305”

DC305 holds part of the evidence:

  • Treatment events and remarks (drug, dose, protocol) show who was treated and when. See DC305 events.

  • Withhold-date items, if the herd uses DC305 treatment protocols, list cows currently in milk or meat withhold.

  • Exits: compare SOLD events against meat-withhold dates to catch cows shipped while in withdrawal:

    EVENTS\D SOLD ID <meat-withhold item> FOR EDAY>-90

    EVENTS lists live animals only by default, so sold animals need \D (animals that have left the herd) or \B (live and left).

Not in DC305: tanker residue screening results (these come from the hauler, processor or regulatory lab), the vet’s written protocols and ELDU orders, drug inventory and storage, and training records.

Typical range

Section titled “Typical range”

Herd context: US dairies shipping Grade A milk; FDA and PMO requirements as of 2026.

  • Tanker screening (PMO Appendix N, 2025 revision): industry must screen every bulk milk pickup tanker (and any raw supply not shipped by tanker) for beta-lactam drug residues, with NCIMS-accepted methods, before the milk is processed. Other drug residues are tested under a random sampling program when FDA determines a potential problem exists. Some states and processors test for more drug families on their own.
  • Target: zero confirmed positive tankers traced to the farm. A positive costs the farm the value of all milk on the contaminated load plus disposal costs (the Appendix N penalty), suspends the permit until the farm’s milk tests negative, and triggers an on-farm investigation.
  • Meat residues: cull dairy cows are among the most frequent sources of residue violations in FSIS testing. In FSIS quarterly reports for FY2023 to FY2025, the violative residues found most often in dairy cows were desfuroylceftiofur (the ceftiofur marker residue), penicillin, ampicillin and flunixin.

Requirements change; confirm the current version with the program or regulator. This page is not legal or veterinary advice.

Common mistakes

Section titled “Common mistakes”
  • Treating a cowside test as proof of compliance. Screening tests detect some drug families at some levels; a negative result does not shorten the withdrawal period.
  • Extra-label use without a written vet order, or without a vet-set extended withdrawal.
  • Lactating-cow and dry-cow products stored together, or products without labels.
  • Cull cows sold in meat withdrawal, especially after a recent anti-inflammatory or a treatment recorded only on paper.
  • Bought-in cows with unknown treatment history entering the milking string.
  • Milking errors: a marked cow milked into the tank, or a hospital-pen unit not switched back to the dump line.
  • Records in several places (paper, treatment board, DC305) that disagree.
  • New or untrained staff treating cows without knowing the protocol.
Section titled “Related”